Three separate studies conducted on Glucozyme™ were unanimously positive for reducing blood sugar levels. The studies measured the fasting glucose levels and the HbA1-c levels of Type 2 diabetics for 30, 60, and 90 days. The results showed that the nutritional supplement reduced blood sugar levels and HbA1-c levels by 22-28% within the study period.
“Following the successful completion of three separate studies, we are very confident that this product is ready for distribution throughout the U.S. and Japanese markets,” said Dr. Tracy K. Gibbs, Nutranomics’ CEO. “Though legally we cannot make any medical claims regarding the treatment of disease with Glucozyme™ I strongly believe that…high-quality dietary supplements can play an important role in providing positive outcomes for people and their families.”
Dr. Gibbs concluded, “A lot of hard work and brain power from the entire Nutranomics team has gone into the development and testing this product, so I’m extremely pleased that it has become a potential breakthrough product for us in 2014. I look forward to discussing the study results and distribution opportunities with our current and potential new customers in the United States and Asia during the coming weeks.”
For more information, visit www.nutranomics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment